Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2016 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences:
- 2016 Wells Fargo Healthcare Conference
Wednesday, September 7th at 2:20 PM Eastern Time
The Westin Boston Waterfront, Boston - Rodman & Renshaw 18th Annual Global Investment Conference
Tuesday, September 13th at 2:10 PM Eastern Time
Lotte New York Palace Hotel, New York
Live webcasts of the presentations will be available on the Sunesis website at http://ir.sunesis.com. Replays of the webcasts will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer. Currently, the company is focused on pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older, as well as advancing its novel kinase-inhibitor pipeline, which includes its proprietary non-covalent BTK-inhibitor, SNS-062.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717
